MaltSci 麦伴科研

Appearance

Popular Reports / structural-biology

This report is written by MaltSci based on the latest literature and research findings

What is the role of protein folding in disease? ​

Abstract ​

Protein folding is a fundamental biological process that ensures proteins achieve their functional three-dimensional structures, crucial for cellular homeostasis. Disruptions in protein folding can lead to a variety of diseases, including neurodegenerative disorders, metabolic syndromes, and cancer. This review synthesizes current findings on the role of protein folding in disease, highlighting the mechanisms involved, the consequences of misfolding, and the therapeutic strategies being developed. The amino acid sequence of proteins plays a pivotal role in determining their folding pathways and stability, with misfolded proteins often aggregating into toxic structures that disrupt cellular function. Molecular chaperones are essential in assisting proper protein folding and preventing aggregation, thereby maintaining proteostasis. Misfolding can lead to cellular dysfunction and is implicated in the pathogenesis of diseases such as Alzheimer's and Parkinson's, where the accumulation of misfolded proteins triggers neurotoxicity. Emerging therapeutic strategies targeting protein misfolding include small molecule chaperones, gene therapy approaches, and immunotherapy. These strategies aim to restore normal protein function or prevent aggregation, offering hope for effective treatments. Future research should focus on novel approaches to study protein folding dynamics and develop innovative therapies, emphasizing the importance of understanding the intricate relationship between protein folding and disease for improving human health.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 The Mechanisms of Protein Folding
    • 2.1 The Role of Amino Acid Sequence
    • 2.2 Chaperones and Their Functions
  • 3 Consequences of Protein Misfolding
    • 3.1 Protein Aggregation and Disease
    • 3.2 Impact on Cellular Function
  • 4 Diseases Associated with Protein Misfolding
    • 4.1 Neurodegenerative Disorders
    • 4.2 Metabolic Disorders
    • 4.3 Cancer
  • 5 Therapeutic Strategies Targeting Protein Misfolding
    • 5.1 Small Molecule Chaperones
    • 5.2 Gene Therapy Approaches
    • 5.3 Immunotherapy
  • 6 Future Directions in Research
    • 6.1 Novel Approaches in Protein Folding Studies
    • 6.2 Implications for Drug Development
  • 7 Summary

1 Introduction ​

Protein folding is a fundamental biological process that ensures proteins achieve their functional three-dimensional structures. This process is critical not only for the proper functioning of proteins but also for maintaining cellular homeostasis. The correct folding of proteins is essential for their biological activity, and any disruption in this intricate process can lead to a variety of diseases, including neurodegenerative disorders, cancer, and metabolic syndromes [1][2]. The significance of protein folding extends beyond basic biology; it is pivotal in understanding the molecular underpinnings of numerous pathologies that afflict human health.

The relationship between protein folding and disease is a burgeoning area of research, revealing that misfolded proteins can aggregate, leading to cellular dysfunction and death. Misfolded proteins often form toxic aggregates that disrupt normal cellular processes, a phenomenon that has been implicated in the pathogenesis of several neurodegenerative diseases, such as Alzheimer's and Parkinson's disease [3][4]. Furthermore, the role of molecular chaperones, which assist in the correct folding of proteins and prevent aggregation, is crucial in maintaining proteostasis [5]. Understanding these mechanisms is vital for developing therapeutic strategies aimed at correcting or preventing protein misfolding.

Current research highlights the complexity of the protein folding process, which is influenced by various factors, including amino acid sequence, cellular environment, and the presence of molecular chaperones [6][7]. Recent advancements in biophysical techniques have allowed researchers to study protein folding dynamics in living cells, providing insights into how proteins fold under physiological conditions and the consequences of misfolding [8]. Despite these advances, challenges remain in accurately predicting protein folding and understanding the multifactorial causes of misfolding, such as genetic mutations, aging, and oxidative stress [9].

This review aims to synthesize current findings on the role of protein folding in disease, structured as follows: First, we will explore the mechanisms of protein folding, focusing on the role of amino acid sequences and molecular chaperones. Next, we will discuss the consequences of protein misfolding, including protein aggregation and its impact on cellular function. We will then examine specific diseases associated with protein misfolding, highlighting neurodegenerative disorders, metabolic disorders, and cancer. Subsequently, we will review emerging therapeutic strategies targeting protein misfolding, such as small molecule chaperones, gene therapy approaches, and immunotherapy. Finally, we will consider future directions in research, emphasizing novel approaches in protein folding studies and their implications for drug development.

By consolidating insights from various studies, this review will provide a comprehensive overview of the intricate relationship between protein folding and disease, underscoring the importance of understanding this process for developing effective treatments and improving human health.

2 The Mechanisms of Protein Folding ​

2.1 The Role of Amino Acid Sequence ​

Protein folding is a critical process that ensures polypeptide chains acquire the correct three-dimensional structures necessary for their biological functions. Disruptions in this process can lead to a pathological state known as dysproteostasis, which is implicated in various diseases, particularly neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. The understanding of protein folding mechanisms is essential for elucidating the pathogenesis of these conditions.

The role of the amino acid sequence in protein folding is fundamental, as it dictates the specific interactions that occur during the folding process. Each protein's unique sequence is shaped by evolutionary processes to promote efficient folding into its native state, which is often stabilized by native-like interactions among residues. However, when proteins misfold, they can aggregate, forming toxic species that contribute to cellular stress and ultimately lead to neurodegeneration [2].

Protein misfolding disorders (PFDs) arise when proteins fail to achieve their proper conformations. For instance, the aggregation of misfolded proteins is a hallmark of diseases like Alzheimer's and transmissible spongiform encephalopathies. The aggregation process can be driven by changes in hydration and packing, as well as by ligand binding, which can either prevent misfolding or promote aggregation [7]. The relationship between protein structure and function is critical, as even slight deviations in folding can result in loss of function or toxic gain of function [10].

Molecular chaperones play a significant role in facilitating proper protein folding and preventing aggregation. They assist nascent polypeptides in reaching their native structures and are crucial in maintaining proteostasis within the cell. Chaperones and other components of the cellular proteostasis network are involved in recognizing misfolded proteins and targeting them for degradation, thus preventing the accumulation of toxic aggregates [5].

Furthermore, the study of protein folding has revealed that the folding process is influenced by various factors, including genetic mutations, aging, and environmental stresses. For example, mutations can lead to alterations in the protein's folding pathway, causing it to misfold and aggregate, which is a common feature in many neurodegenerative diseases [3].

In summary, the amino acid sequence is paramount in determining the folding pathway and stability of proteins. Misfolding and aggregation of proteins due to disruptions in this process can lead to significant cellular dysfunction and contribute to the pathogenesis of numerous diseases. Understanding the intricate mechanisms of protein folding not only provides insights into disease mechanisms but also highlights potential therapeutic avenues for intervention [1][6].

2.2 Chaperones and Their Functions ​

Protein folding is a critical biological process that ensures polypeptide chains acquire the correct three-dimensional structures necessary for their functionality. Properly folded proteins are essential for cellular health, while misfolded proteins can lead to a pathological state known as dysproteostasis, which is implicated in various diseases, including neurodegenerative disorders, metabolic syndromes, and cancer [1].

The folding of proteins is facilitated by molecular chaperones, which are specialized proteins that assist in the proper folding of other proteins and prevent aggregation, particularly under stress conditions. These chaperones function by binding to nascent or misfolded proteins, thereby preventing their aggregation and directing them toward correct folding pathways [11]. The heat shock protein 90 (Hsp90), for instance, is a major regulator of protein folding across eukaryotic cells, and its activity is closely regulated by co-chaperones [11].

Disruptions in the protein folding process can result from various factors, including genetic mutations, aging, and oxidative stress. Such disruptions lead to the formation of toxic protein aggregates, which are hallmarks of many neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease [12]. In these conditions, the accumulation of misfolded proteins can lead to cellular dysfunction and death. For example, in Parkinson's disease, the misfolding of α-synuclein protein results in the formation of Lewy bodies, which are characteristic of the disease [12].

Chaperones play a multifaceted role in maintaining proteostasis. They are involved not only in assisting protein folding but also in the degradation of irreversibly misfolded proteins through pathways such as the ubiquitin-proteasome system and autophagy [12]. The balance between the synthesis of chaperones and the demand for protein folding is crucial; an imbalance can exacerbate the progression of diseases characterized by protein misfolding [1].

Recent studies have highlighted therapeutic innovations aimed at modulating the proteostasis network. These include chaperone modulators and inhibitors of proteostasis pathways, which aim to enhance the resilience of the proteome against misfolding [1]. Additionally, small molecule activators of the heat shock response (HSR) have shown promise in promoting the synthesis of chaperones, thereby potentially mitigating the effects of protein misfolding associated with aging and neurodegenerative diseases [13].

In summary, the role of protein folding in disease is significant, as proper folding is essential for protein functionality. The involvement of molecular chaperones in assisting and regulating this process is crucial for maintaining cellular health, and therapeutic strategies targeting chaperone function represent a promising avenue for addressing diseases related to protein misfolding and aggregation.

3 Consequences of Protein Misfolding ​

3.1 Protein Aggregation and Disease ​

Protein folding is a critical process that determines the three-dimensional structure and functionality of proteins, which are essential for various biological processes. When proteins misfold, it can lead to aggregation, a phenomenon that is closely associated with numerous diseases, particularly neurodegenerative disorders.

Misfolded proteins often aggregate and accumulate, triggering neurotoxicity through cellular stress pathways. This disruption of protein homeostasis, or proteostasis, is a central pathogenic mechanism in many neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) [2]. The accumulation of these aggregates can lead to neuronal dysfunction and cell death, which are hallmarks of these conditions. For instance, in ALS, the disease manifests with the presence of protein aggregates in affected tissues, indicating that proteostasis disruption plays a critical role in its pathogenesis [14].

The specific nature of protein aggregation varies by disease. In Alzheimer's disease, for example, amyloid-beta peptides aggregate to form plaques, while tau protein hyperphosphorylation leads to the formation of neurofibrillary tangles [15]. In Parkinson's disease, alpha-synuclein misfolds and aggregates into Lewy bodies [15]. Each of these aggregated forms induces specific pathological processes that contribute to the overall neurodegenerative effect.

The mechanisms leading to protein misfolding and aggregation are complex and multifactorial. Factors such as genetic mutations, errors in protein synthesis and trafficking, and failures in the chaperone machinery can all contribute to the misfolding process [14]. Furthermore, environmental factors like pH, temperature, and the presence of certain ligands can also influence protein stability and folding [7].

The consequences of protein misfolding extend beyond mere structural changes; they can lead to loss of function, gain of toxic properties, and the formation of cytotoxic aggregates [16]. The aggregates formed can vary in structure and morphology, and many of them are highly cytotoxic, contributing to cell death and disease progression [16].

In summary, protein folding is crucial for maintaining cellular function, and its disruption can lead to a cascade of events resulting in protein misfolding and aggregation. This aggregation is a common pathological feature of several neurodegenerative diseases, emphasizing the importance of understanding these processes to develop effective therapeutic strategies aimed at preventing or treating these debilitating conditions [17].

3.2 Impact on Cellular Function ​

Protein folding is a critical process that determines the three-dimensional structure and function of proteins, which are essential for various biological processes. Proper protein folding is facilitated by molecular chaperones and is intricately linked to numerous cellular functions, including transcription, translation, post-translational modifications, and degradation mechanisms such as the ubiquitin-proteasome system and autophagy. When this delicate process is disrupted, it can lead to protein misfolding, a phenomenon that is central to the pathology of many neurodegenerative diseases.

The consequences of protein misfolding are profound and multifaceted. Misfolded proteins often aggregate, forming toxic oligomers and fibrils that can trigger cellular stress pathways. This aggregation is particularly detrimental in neurons, where it can lead to neurotoxicity and ultimately cell death. The specific manifestation of diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease is often dependent on the brain region affected by these toxic aggregates [2].

The accumulation of misfolded proteins can overwhelm the cellular quality control systems, leading to a condition known as proteostasis collapse. In healthy cells, the protein quality control (PQC) systems effectively manage misfolded proteins, but as cells age or in certain genetic conditions, these systems may become less efficient, resulting in increased levels of misfolded proteins. This accumulation can disrupt normal cellular functions, contributing to the pathology of various diseases [18].

Moreover, the misfolding of proteins can lead to a loss of their normal function or, conversely, a gain of toxic function. For example, in diseases like amyotrophic lateral sclerosis (ALS) and Alzheimer's disease, misfolded proteins not only lose their biological activity but also acquire harmful properties that initiate and propagate neurodegenerative processes [19]. The toxic effects of these aggregates can manifest through various mechanisms, including disruption of cell membranes, inactivation of functional proteins, and interference with cellular quality control systems [20].

The impact of protein misfolding extends beyond cell death; it also includes more subtle forms of cellular damage, such as impaired synaptic plasticity and disrupted communication between neurons [2]. As the incidence of neurodegenerative diseases is expected to rise with increasing life expectancy, understanding the role of protein folding and misfolding in cellular function is crucial for developing effective therapeutic strategies [2].

Current therapeutic approaches focus on a variety of strategies to address protein misfolding disorders, including inhibiting the aggregation of misfolded proteins, enhancing the degradation of toxic aggregates, and restoring normal protein function [19]. By targeting the fundamental mechanisms of protein misfolding, researchers aim to mitigate the detrimental effects on cellular function and ultimately improve outcomes for individuals affected by these debilitating conditions.

4 Diseases Associated with Protein Misfolding ​

4.1 Neurodegenerative Disorders ​

Protein folding is a critical process for maintaining cellular function, and its disruption is a central feature in various neurodegenerative disorders. Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are characterized by the misfolding and aggregation of specific proteins, which can lead to cellular toxicity and neurodegeneration.

Proper protein folding is essential for achieving the correct secondary and tertiary structures necessary for protein functionality. When proteins misfold, they can lose their normal function or gain toxic properties, often leading to the formation of aggregates. These aggregates can trigger a series of biological responses that are detrimental to cellular health, primarily affecting neurons (Scannevin 2018; Gandhi et al. 2019). The aggregation of misfolded proteins can overwhelm the cellular quality control systems, such as molecular chaperones and the ubiquitin-proteasome system, which are designed to refold or degrade misfolded proteins (Chaudhuri & Paul 2006; Joshi et al. 2020).

In neurodegenerative diseases, the accumulation of misfolded proteins correlates with cognitive and motor impairments observed in patients. For instance, in Alzheimer's disease, the aggregation of amyloid-beta and hyperphosphorylated tau proteins leads to the formation of plaques and tangles, respectively, which are hallmarks of the disease (Zilka et al. 2008). Similarly, in Parkinson's disease, the misfolding of α-synuclein results in the formation of Lewy bodies, contributing to the progressive degeneration of dopaminergic neurons (Ebrahimi-Fakhari et al. 2013).

The pathogenesis of these disorders often involves a cascade of events initiated by protein misfolding, which can lead to cellular stress, inflammation, and ultimately cell death (Miranda & Outeiro 2010). This process is exacerbated by age-related factors, as the incidence of neurodegenerative diseases increases with longer life expectancy, highlighting the significance of protein homeostasis in aging populations (Gandhi et al. 2019).

To combat the detrimental effects of protein misfolding, various therapeutic strategies are being explored. These include the development of small molecules that enhance the function of molecular chaperones, inhibit the aggregation of misfolded proteins, or promote the clearance of aggregates through autophagy or the ubiquitin-proteasome system (Jackrel & Shorter 2017; Chaari 2019). Additionally, the manipulation of chaperone activity and the use of engineered protein-remodeling factors show promise in reversing misfolding and restoring normal protein function (Jackrel & Shorter 2017).

In summary, protein folding plays a crucial role in neurodegenerative diseases, where misfolding and aggregation of proteins lead to neurotoxicity and cellular dysfunction. Understanding the mechanisms of protein misfolding and exploring therapeutic avenues to restore protein homeostasis are vital for developing effective treatments for these debilitating conditions.

4.2 Metabolic Disorders ​

Protein folding is a critical biological process that ensures polypeptide chains acquire the correct three-dimensional structures necessary for their biological functions. Disruptions in this process can lead to a pathological state known as dysproteostasis, which is implicated in various human diseases, including metabolic disorders. Misfolded proteins can result from genetic mutations, adverse physiological conditions, or the accumulation of toxic aggregates, leading to a range of metabolic diseases.

In the context of metabolic disorders, protein misfolding often arises from missense mutations, which are the most frequent type of genetic defect in these conditions. Such mutations frequently lead to defective protein folding, causing a cascade of cellular dysfunction. For example, therapies utilizing small molecules, termed pharmacological chaperones, have been developed to correct protein folding defects in metabolic diseases like phenylketonuria and Gaucher's disease. These small molecules interact directly with specific proteins to stabilize their correct conformations, thereby restoring function [21].

The interplay between cofactors, metabolites, and protein folding is also significant in metabolic diseases. Recent studies have highlighted the synergistic effects of vitamins and cofactors in correcting protein misfolding. For instance, riboflavin supplementation has been shown to be effective in treating fatty acid β-oxidation disorders, with evidence suggesting that multiple small molecules may work together to enhance the stability and functionality of defective enzymes [21].

Moreover, protein misfolding in metabolic disorders can lead to the formation of aggregates that disrupt normal cellular processes. For example, in Type 2 diabetes mellitus (T2DM), misfolded proteins such as islet amyloid polypeptide (IAPP) aggregate within pancreatic beta cells, contributing to cell dysfunction and apoptosis. This aggregation not only affects insulin secretion but also exacerbates the overall metabolic dysfunction [22].

The mechanisms underlying protein misfolding in metabolic diseases are complex and multifactorial, involving not only genetic factors but also environmental stressors, such as oxidative stress and aging. The accumulation of misfolded proteins can trigger cellular stress responses, including the unfolded protein response (UPR), which aims to restore normal function but can also lead to inflammation and cell death if the stress is unresolved [23].

In summary, the role of protein folding in metabolic disorders is pivotal, as proper folding is essential for maintaining cellular homeostasis. The failure of proteins to fold correctly can lead to metabolic dysfunction, highlighting the importance of understanding the molecular mechanisms of protein misfolding and the development of therapeutic strategies to mitigate these effects. Efforts to correct protein folding defects through pharmacological interventions represent a promising avenue for treating various metabolic diseases [21][22].

4.3 Cancer ​

Protein folding is a critical biological process that ensures proteins attain their functional three-dimensional structures. Misfolding, however, can lead to the formation of aggregates and dysfunctional proteins, which are often associated with various diseases, including cancer. In the context of cancer, the implications of protein misfolding are significant and multifaceted.

Protein misfolding is implicated in a range of diseases termed protein-folding disorders (PFDs), which include not only neurodegenerative diseases like Alzheimer's and Parkinson's but also cancers. Misfolded proteins can disrupt normal cellular functions, leading to cellular dysfunction and contributing to tumorigenesis. The correct folding of proteins is essential for their biological activity, and misfolding can result in loss of function or gain of toxic function, both of which can promote cancer development[7].

A key player in the folding process is prefoldin, a chaperone protein that regulates the correct folding of proteins. Prefoldin has been shown to play a crucial role in the pathogenesis of common neurodegenerative diseases, and its function is also relevant in cancer. Abnormal expression of prefoldin and its subunits can influence tumorigenesis and the development of cancer by affecting the folding and stability of proteins involved in cell growth and differentiation[3].

Moreover, the interaction between protein misfolding and cellular environments is complex. The presence of macromolecular crowding and various post-translational modifications can significantly impact protein folding within cells. In cancer cells, these factors may alter the normal folding pathways, leading to an increased propensity for misfolding and aggregation of proteins, which in turn may promote tumor progression[8].

The therapeutic landscape for addressing protein misfolding in cancer is evolving. Small molecules that stabilize the native state of misfolding-prone proteins have shown promise in preclinical studies. For instance, certain small molecules have been identified that can bind to and stabilize misfolded proteins, thereby restoring their function and potentially reversing the pathological processes associated with cancer[24].

In summary, protein folding plays a pivotal role in maintaining cellular homeostasis, and its failure due to misfolding can lead to significant pathological consequences, including cancer. Understanding the mechanisms underlying protein misfolding and the cellular responses to misfolded proteins is essential for developing targeted therapies aimed at treating cancer and other diseases associated with protein misfolding.

5 Therapeutic Strategies Targeting Protein Misfolding ​

5.1 Small Molecule Chaperones ​

Protein folding is a critical biological process whereby polypeptide chains acquire their correct three-dimensional structures, which are essential for their functional roles within the cell. Disruptions in this intricate process can lead to a pathological state known as dysproteostasis, which is implicated in various human diseases, including neurodegenerative disorders, metabolic syndromes, and cancer [1].

In particular, protein misfolding is a significant factor in many neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's disease. These conditions are often characterized by the accumulation of toxic protein aggregates that result from misfolded proteins, ultimately leading to neuronal cell death and dysfunction [25]. The cellular defense mechanisms, including molecular chaperones and the ubiquitin-proteasome system, play a crucial role in monitoring protein folding and facilitating the degradation of improperly folded proteins [26].

Small molecule chaperones, also known as pharmacological chaperones, have emerged as a promising therapeutic strategy for addressing protein misfolding diseases. These compounds are designed to bind specifically to misfolded proteins, stabilizing them and promoting their proper folding and trafficking [27]. By enhancing the native-like folding of proteins, pharmacological chaperones can help restore normal function and prevent the toxic effects associated with misfolded proteins [28].

The mechanism of action of these small molecules involves providing a molecular scaffold that assists in the correct folding of proteins, thereby reducing the energetic barriers associated with folding [29]. This is particularly important in diseases where genetic mutations lead to conformational defects in proteins, resulting in their misrouting or premature degradation [30]. For example, pharmacological chaperones have been successfully applied in the treatment of lysosomal storage diseases, where they help restore the function of misfolded enzymes [31].

Moreover, the development of second-generation pharmacological chaperones aims to improve upon the limitations of first-generation compounds, which often acted as competitive inhibitors. The newer compounds are designed to target previously unknown binding sites, thereby enhancing the specificity and efficacy of the treatment without the risk of inhibiting the protein's activity [30].

In summary, the role of protein folding in disease is pivotal, as misfolding can lead to a cascade of cellular dysfunctions and disease states. Therapeutic strategies that employ small molecule chaperones represent a novel and effective approach to mitigate the consequences of protein misfolding, offering hope for the treatment of various conformational diseases.

5.2 Gene Therapy Approaches ​

Protein folding is a critical biological process whereby polypeptide chains acquire their correct three-dimensional structures, essential for their functional roles in the cell. Disruptions in this intricate process can lead to a pathological state known as dysproteostasis, which is implicated in various human diseases, including neurodegenerative disorders, metabolic syndromes, and cancer. The accumulation of misfolded proteins often results in toxic aggregates that can cause cell death and dysfunction, leading to clinical manifestations characteristic of diseases such as Alzheimer's, Parkinson's, and Huntington's disease (Kuzu et al., 2025; Bose & Cho, 2017; Scannevin, 2018).

The therapeutic strategies targeting protein misfolding focus on restoring proper protein function or preventing the aggregation of misfolded proteins. These strategies include the use of molecular chaperones, which assist in the correct folding of proteins and the removal of misfolded proteins through the ubiquitin-proteasome system and autophagy. Research has shown that enhancing the activity of these chaperones can be a promising approach to mitigate the effects of protein misfolding (Rochet, 2007; Uversky et al., 2006; Vendruscolo, 2023).

Gene therapy approaches have emerged as a novel strategy to combat protein misfolding diseases. This involves the delivery of therapeutic genes that encode for molecular chaperones or other proteins that can assist in the proper folding of disease-associated proteins. For instance, the introduction of genes that enhance the expression of chaperones could potentially improve the cellular environment for protein folding, thereby reducing the incidence of misfolding and aggregation (Gomes, 2012; Gavrin et al., 2012; Cardinale & Biocca, 2008).

Additionally, small molecules that target specific misfolded proteins have been developed. These molecules can stabilize the native conformation of proteins or promote the degradation of misfolded variants. For example, tafamidis, a small molecule that binds to the folded state of transthyretin, has been approved for the treatment of transthyretin amyloidosis, illustrating the potential of small molecules in treating protein misfolding disorders (Chiti & Kelly, 2022; Vendruscolo, 2023).

In summary, protein folding plays a pivotal role in maintaining cellular homeostasis, and its dysregulation is central to many diseases. Therapeutic strategies, including the use of molecular chaperones and gene therapy approaches, offer promising avenues for addressing the challenges posed by protein misfolding and aggregation, paving the way for novel interventions in the treatment of these debilitating disorders.

5.3 Immunotherapy ​

Protein folding is a fundamental biological process essential for the proper function of proteins. When proteins misfold, they can lead to various diseases, particularly neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Misfolded proteins often aggregate, forming toxic structures that disrupt cellular function and ultimately result in cell death [2][19][25].

The misfolding and aggregation of proteins can occur due to several factors, including genetic mutations, oxidative stress, and aging. These factors disrupt the delicate balance of the cellular proteostasis network, which includes molecular chaperones and degradation systems that normally help proteins fold correctly and maintain their functional conformations [1]. The accumulation of misfolded proteins triggers neurotoxicity through cellular stress pathways, leading to neurodegenerative diseases characterized by the loss of neurons and associated clinical manifestations [2].

Therapeutic strategies targeting protein misfolding are an emerging field of interest. These strategies include the development of small molecules that act as pharmacological chaperones to stabilize misfolded proteins, inhibit their aggregation, or promote their proper folding [25][32]. For instance, compounds that enhance the activity of molecular chaperones or inhibit pathways leading to protein misfolding are being explored as potential treatments [33].

Immunotherapy represents a promising approach within the therapeutic landscape for addressing protein misfolding diseases. This strategy leverages the body's immune system to target and neutralize misfolded proteins or their aggregates. For example, antibody-based therapies, including intrabodies, are being developed to specifically recognize and bind to misfolded protein conformations, thereby preventing their aggregation and facilitating their clearance from cells [34]. Such immunotherapeutic approaches hold the potential to address the underlying causes of neurodegenerative diseases by targeting the pathological forms of proteins directly.

In summary, protein folding is crucial for cellular health, and its disruption can lead to severe diseases. Therapeutic strategies targeting protein misfolding, including small molecules and immunotherapy, offer new avenues for intervention in neurodegenerative disorders, highlighting the importance of restoring proteostasis and preventing toxic protein aggregation.

6 Future Directions in Research ​

6.1 Novel Approaches in Protein Folding Studies ​

Protein folding is a fundamental process essential for the proper functioning of proteins, and its disruption can lead to a range of diseases, particularly neurodegenerative disorders, metabolic syndromes, and cancer. The cellular proteostasis network, which includes molecular chaperones and degradation machineries, plays a crucial role in ensuring proteins achieve their correct three-dimensional structures. When this network is compromised, it results in dysproteostasis, a pathological state that can lead to the formation of toxic protein aggregates, ultimately causing cellular dysfunction and disease[1].

Research has shown that protein misfolding is often linked to specific diseases. For instance, Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β peptide aggregates and tau protein tangles, which disrupt neuronal function and contribute to cognitive decline. These aggregates form as a result of failed protein folding and clearance mechanisms, highlighting the critical role of protein homeostasis in maintaining cellular health[23]. Moreover, the endoplasmic reticulum (ER) stress response is activated in conditions of misfolded proteins, leading to an unfolded protein response (UPR) aimed at restoring normal folding capacity. However, chronic ER stress can trigger apoptosis and exacerbate neurodegeneration[35].

Future research directions in the field of protein folding and its implications in disease will likely focus on several novel approaches. First, the development of advanced biophysical techniques, such as single-molecule fluorescence spectroscopy and optical tweezers, will enable the study of protein folding dynamics in living cells. This will allow researchers to monitor the effects of various cellular components, including molecular chaperones, on protein folding processes in real-time[8].

Additionally, there is a growing interest in exploring the role of post-translational modifications, such as proline isomerization, in regulating protein folding and function. Understanding how these modifications affect the stability and folding pathways of proteins could lead to new therapeutic strategies targeting protein misfolding diseases[36].

Moreover, the investigation of pharmacological agents that can enhance the heat shock response (HSR) is another promising area. These agents could potentially increase the expression of heat shock proteins (HSPs), which are crucial for maintaining proteostasis and preventing misfolding[13]. Identifying small molecule activators of the HSR may provide new avenues for treating diseases associated with protein misfolding, such as AD and other neurodegenerative conditions[37].

Finally, the application of computational modeling techniques, including Markov state models (MSMs), can offer insights into the energy landscapes and folding mechanisms of proteins. This computational approach can help identify the pathways leading to misfolding and aggregation, thus informing the design of novel therapeutic interventions[6].

In summary, the role of protein folding in disease is critical, with misfolding being implicated in a variety of pathologies. Future research is poised to leverage advanced experimental techniques, explore the impact of post-translational modifications, enhance proteostasis through pharmacological means, and utilize computational models to deepen our understanding of protein folding dynamics and its relationship to disease.

6.2 Implications for Drug Development ​

Protein folding plays a crucial role in maintaining cellular function and overall health. Properly folded proteins are essential for biological processes, while misfolding can lead to the formation of aggregates and dysfunctional proteins, which are often associated with various diseases. Disruptions in the protein folding process can result in a pathological state known as dysproteostasis, which has been implicated in a range of human diseases, including neurodegenerative disorders, metabolic syndromes, and cancer [1].

The complexity of protein folding is underscored by the fact that it is influenced by multiple factors, including genetic mutations, aging, and oxidative stress. Misfolded proteins can aggregate, leading to toxic effects within cells and contributing to diseases characterized by protein aggregation, such as Alzheimer's disease [8]. For instance, specific mutations within genes can result in proteins that fail to achieve stable conformations, triggering cellular quality control mechanisms that target these abnormally folded proteins for degradation [38]. The failure of these mechanisms can lead to chronic cellular stress and the eventual demise of cells [39].

Research into protein folding has progressed significantly, integrating theoretical models with experimental approaches to understand the underlying mechanisms of folding and misfolding [6]. Advanced biophysical techniques, such as fluorescence resonance energy transfer (FRET) and nuclear magnetic resonance (NMR), have been employed to study protein folding in living cells, allowing for a more nuanced understanding of how cellular environments affect folding dynamics [8].

In terms of future research directions, there is a pressing need to develop new methods—both theoretical and experimental—that can accurately quantify the folding behavior of a broad range of proteins under physiological conditions [37]. This shift is essential for linking protein folding mechanisms to disease pathology and for understanding the molecular basis of various disorders.

The implications for drug development are significant. The identification of small molecules that can stabilize the native state of misfolding-prone proteins has emerged as a promising therapeutic strategy. For example, tafamidis, the first small molecule approved for treating a protein misfolding disease, specifically binds to the folded state of transthyretin, thereby correcting cellular folding or stabilizing the protein against misfolding and aggregation [24]. This approach has been expanded to include several other pathologies, suggesting that targeting protein folding pathways could provide new avenues for therapeutic intervention.

Overall, the ongoing research into protein folding and its implications for health and disease not only enhances our understanding of fundamental biological processes but also paves the way for innovative therapeutic strategies aimed at correcting or mitigating the effects of protein misfolding. As we continue to unravel the complexities of protein folding, the potential for developing effective treatments for a variety of diseases linked to misfolded proteins becomes increasingly viable.

7 Conclusion ​

The exploration of protein folding mechanisms reveals significant insights into the pathogenesis of various diseases, particularly neurodegenerative disorders, metabolic syndromes, and cancer. Misfolding and aggregation of proteins are critical factors leading to cellular dysfunction and disease progression. Current research emphasizes the pivotal role of molecular chaperones in maintaining proteostasis and the consequences of their dysfunction. While advancements in therapeutic strategies, including small molecule chaperones, gene therapy, and immunotherapy, show promise, challenges remain in effectively targeting protein misfolding. Future research should focus on innovative approaches, such as advanced biophysical techniques and computational modeling, to deepen our understanding of protein folding dynamics. By unraveling these complexities, we can pave the way for novel interventions that restore protein homeostasis and improve outcomes for patients suffering from diseases associated with protein misfolding. The integration of findings from protein folding studies into drug development strategies is essential for creating effective therapies that target the underlying mechanisms of these debilitating conditions.

References ​

  • [1] Omer Faruk Kuzu;Lars Jørgen Tvenge Granerud;Fahri Saatcioglu. Navigating the landscape of protein folding and proteostasis: from molecular chaperones to therapeutic innovations.. Signal transduction and targeted therapy(IF=52.7). 2025. PMID:41130962. DOI: 10.1038/s41392-025-02439-w.
  • [2] Jason Gandhi;Anthony C Antonelli;Adil Afridi;Sohrab Vatsia;Gunjan Joshi;Victor Romanov;Ian V J Murray;Sardar Ali Khan. Protein misfolding and aggregation in neurodegenerative diseases: a review of pathogeneses, novel detection strategies, and potential therapeutics.. Reviews in the neurosciences(IF=4.1). 2019. PMID:30742586. DOI: 10.1515/revneuro-2016-0035.
  • [3] Jiaxin Liang;Longzheng Xia;Linda Oyang;Jinguan Lin;Shiming Tan;Pin Yi;Yaqian Han;Xia Luo;Hui Wang;Lu Tang;Qing Pan;Yutong Tian;Shan Rao;Min Su;Yingrui Shi;Deliang Cao;Yujuan Zhou;Qianjin Liao. The functions and mechanisms of prefoldin complex and prefoldin-subunits.. Cell & bioscience(IF=6.2). 2020. PMID:32699605. DOI: 10.1186/s13578-020-00446-8.
  • [4] Aislinn J Williams;Henry L Paulson. Polyglutamine neurodegeneration: protein misfolding revisited.. Trends in neurosciences(IF=15.1). 2008. PMID:18778858. DOI: 10.1016/j.tins.2008.07.004.
  • [5] Zijue Huang;Scott Horowitz. Catalyzing Protein Folding by Chaperones.. Biology(IF=3.5). 2025. PMID:41154852. DOI: 10.3390/biology14101450.
  • [6] Gregory R Bowman;Vincent A Voelz;Vijay S Pande. Taming the complexity of protein folding.. Current opinion in structural biology(IF=7.0). 2011. PMID:21081274. DOI: 10.1016/j.sbi.2010.10.006.
  • [7] Jerson L Silva;Tuane C R G Vieira;Mariana P B Gomes;Ana Paula Ano Bom;Luis Mauricio T R Lima;Monica S Freitas;Daniella Ishimaru;Yraima Cordeiro;Debora Foguel. Ligand binding and hydration in protein misfolding: insights from studies of prion and p53 tumor suppressor proteins.. Accounts of chemical research(IF=17.7). 2010. PMID:19817406. DOI: 10.1021/ar900179t.
  • [8] Hong Zhang;Weibin Gong;Si Wu;Sarah Perrett. Studying protein folding in health and disease using biophysical approaches.. Emerging topics in life sciences(IF=3.3). 2021. PMID:33660767. DOI: 10.1042/ETLS20200317.
  • [9] Karolina Corin;James U Bowie. How physical forces drive the process of helical membrane protein folding.. EMBO reports(IF=6.2). 2022. PMID:35133709. DOI: 10.15252/embr.202153025.
  • [10] C M Dobson. The structural basis of protein folding and its links with human disease.. Philosophical transactions of the Royal Society of London. Series B, Biological sciences(IF=4.7). 2001. PMID:11260793. DOI: 10.1098/rstb.2000.0758.
  • [11] Anastasiia Bohush;Paweł Bieganowski;Anna Filipek. Hsp90 and Its Co-Chaperones in Neurodegenerative Diseases.. International journal of molecular sciences(IF=4.9). 2019. PMID:31600883. DOI: 10.3390/ijms20204976.
  • [12] Darius Ebrahimi-Fakhari;Lara Wahlster;Pamela J McLean. Molecular chaperones in Parkinson's disease--present and future.. Journal of Parkinson's disease(IF=5.0). 2011. PMID:22279517. DOI: .
  • [13] James D West;Yanyu Wang;Kevin A Morano. Small molecule activators of the heat shock response: chemical properties, molecular targets, and therapeutic promise.. Chemical research in toxicology(IF=3.8). 2012. PMID:22799889. DOI: 10.1021/tx300264x.
  • [14] Ouliana Ivantsik;Themis P Exarchos;Aristidis G Vrahatis;Panagiotis Vlamos;Marios G Krokidis. Exploring Protein Misfolding in Amyotrophic Lateral Sclerosis: Structural and Functional Insights.. Biomedicines(IF=3.9). 2025. PMID:40426973. DOI: 10.3390/biomedicines13051146.
  • [15] Sandra Tenreiro;Katrin Eckermann;Tiago F Outeiro. Protein phosphorylation in neurodegeneration: friend or foe?. Frontiers in molecular neuroscience(IF=3.8). 2014. PMID:24860424. DOI: 10.3389/fnmol.2014.00042.
  • [16] Vijay Kumar;Neha Sami;Tara Kashav;Asimul Islam;Faizan Ahmad;Md Imtaiyaz Hassan. Protein aggregation and neurodegenerative diseases: From theory to therapy.. European journal of medicinal chemistry(IF=5.9). 2016. PMID:27486076. DOI: 10.1016/j.ejmech.2016.07.054.
  • [17] Ishfaq Ahmad Ahanger;Ghulam Md Ashraf;Anurag Sharma;Asimul Islam. Comprehensive Perspective Towards the Management of Proteinopathies by Elucidating Protein Misfolding and Aggregation.. CNS & neurological disorders drug targets(IF=3.0). 2024. PMID:36876837. DOI: 10.2174/1871527322666230306085937.
  • [18] Niels Gregersen;Peter Bross;Søren Vang;Jane H Christensen. Protein misfolding and human disease.. Annual review of genomics and human genetics(IF=7.9). 2006. PMID:16722804. DOI: 10.1146/annurev.genom.7.080505.115737.
  • [19] Robert H Scannevin. Therapeutic strategies for targeting neurodegenerative protein misfolding disorders.. Current opinion in chemical biology(IF=6.1). 2018. PMID:29902695. DOI: 10.1016/j.cbpa.2018.05.018.
  • [20] Stephen C Meredith. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.. Annals of the New York Academy of Sciences(IF=4.8). 2005. PMID:16533927. DOI: 10.1196/annals.1363.030.
  • [21] João V Rodrigues;Bárbara J Henriques;Tânia G Lucas;Cláudio M Gomes. Cofactors and metabolites as protein folding helpers in metabolic diseases.. Current topics in medicinal chemistry(IF=3.3). 2012. PMID:23339307. DOI: 10.2174/1568026611212220009.
  • [22] Ghulam M Ashraf;Nigel H Greig;Taqi A Khan;Iftekhar Hassan;Shams Tabrez;Shazi Shakil;Ishfaq A Sheikh;Syed K Zaidi;Mohammad Akram;Nasimudeen R Jabir;Chelaprom K Firoz;Aabgeena Naeem;Ibrahim M Alhazza;Ghazi A Damanhouri;Mohammad A Kamal. Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus.. CNS & neurological disorders drug targets(IF=3.0). 2014. PMID:25230234. DOI: 10.2174/1871527313666140917095514.
  • [23] Luis E Santos;Sergio T Ferreira. Crosstalk between endoplasmic reticulum stress and brain inflammation in Alzheimer's disease.. Neuropharmacology(IF=4.6). 2018. PMID:29129774. DOI: 10.1016/j.neuropharm.2017.11.016.
  • [24] Fabrizio Chiti;Jeffery W Kelly. Small molecule protein binding to correct cellular folding or stabilize the native state against misfolding and aggregation.. Current opinion in structural biology(IF=7.0). 2022. PMID:34999558. DOI: 10.1016/j.sbi.2021.11.009.
  • [25] Shambhunath Bose;Jungsook Cho. Targeting chaperones, heat shock factor-1, and unfolded protein response: Promising therapeutic approaches for neurodegenerative disorders.. Ageing research reviews(IF=12.4). 2017. PMID:27702699. DOI: 10.1016/j.arr.2016.09.004.
  • [26] Sandeep K Sharma;Smriti Priya. Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.. Cellular and molecular life sciences : CMLS(IF=6.2). 2017. PMID:27522545. DOI: 10.1007/s00018-016-2340-9.
  • [27] Ya-Xiong Tao;P Michael Conn. Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.. Physiological reviews(IF=28.7). 2018. PMID:29442594. DOI: 10.1152/physrev.00029.2016.
  • [28] Ya-Juan Wang;Xiao-Jing Di;Ting-Wei Mu. Using pharmacological chaperones to restore proteostasis.. Pharmacological research(IF=10.5). 2014. PMID:24747662. DOI: .
  • [29] Marino Convertino;Jhuma Das;Nikolay V Dokholyan. Pharmacological Chaperones: Design and Development of New Therapeutic Strategies for the Treatment of Conformational Diseases.. ACS chemical biology(IF=3.8). 2016. PMID:27097127. DOI: 10.1021/acschembio.6b00195.
  • [30] My Lan Tran;Yves Génisson;Stéphanie Ballereau;Cécile Dehoux. Second-Generation Pharmacological Chaperones: Beyond Inhibitors.. Molecules (Basel, Switzerland)(IF=4.6). 2020. PMID:32660097. DOI: 10.3390/molecules25143145.
  • [31] David M Pereira;Patrícia Valentão;Paula B Andrade. Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones.. Chemical science(IF=7.4). 2018. PMID:29719681. DOI: 10.1039/c7sc04712f.
  • [32] Cláudio M Gomes. Protein misfolding in disease and small molecule therapies.. Current topics in medicinal chemistry(IF=3.3). 2012. PMID:23339300. DOI: 10.2174/1568026611212220002.
  • [33] Tiago Fleming Outeiro;Günter Höglinger;Anthony E Lang;Tuane C R G Vieira. Protein misfolding: understanding biology to classify and treat synucleinopathies.. Journal of neural transmission (Vienna, Austria : 1996)(IF=4.0). 2025. PMID:39932548. DOI: 10.1007/s00702-025-02889-0.
  • [34] Alessio Cardinale;Silvia Biocca. The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases.. Trends in molecular medicine(IF=13.8). 2008. PMID:18693139. DOI: 10.1016/j.molmed.2008.07.004.
  • [35] Hamid Mollazadeh;Stephen L Atkin;Alexandra E Butler;Massimiliano Ruscica;Cesare R Sirtori;Amirhossein Sahebkar. The effect of statin therapy on endoplasmic reticulum stress.. Pharmacological research(IF=10.5). 2018. PMID:30312664. DOI: 10.1016/j.phrs.2018.10.006.
  • [36] Deepti Gurung;Jacob A Danielson;Afsara Tasnim;Jian-Ting Zhang;Yue Zou;Jing-Yuan Liu. Proline Isomerization: From the Chemistry and Biology to Therapeutic Opportunities.. Biology(IF=3.5). 2023. PMID:37508437. DOI: 10.3390/biology12071008.
  • [37] Esther Braselmann;Julie L Chaney;Patricia L Clark. Folding the proteome.. Trends in biochemical sciences(IF=11.0). 2013. PMID:23764454. DOI: .
  • [38] William J Welch. Role of quality control pathways in human diseases involving protein misfolding.. Seminars in cell & developmental biology(IF=6.0). 2004. PMID:15036204. DOI: 10.1016/j.semcdb.2003.12.011.
  • [39] William E Balch;Jacob I Sznajder;Scott Budinger;Daniel Finley;Aaron D Laposky;Ana Maria Cuervo;Ivor J Benjamin;Esther Barreiro;Richard I Morimoto;Lisa Postow;Allan M Weissman;Dorothy Gail;Susan Banks-Schlegel;Thomas Croxton;Weiniu Gan. Malfolded protein structure and proteostasis in lung diseases.. American journal of respiratory and critical care medicine(IF=19.4). 2014. PMID:24033344. DOI: 10.1164/rccm.201306-1164WS.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Protein Folding · Disease · Misfolding · Neurodegenerative Disorders · Therapeutic Strategies

© 2025 MaltSci